SynthesisClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Economic Evaluations of Mass Drug Administration: The Importance of Economies of Scale and Scope.
Synthesis in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Economic evaluations of scaling up strategies of evidence-based health interventions: a systematic review.BMC health services research · 2025Pooled it
- Economic evaluations of human schistosomiasis interventions: a systematic review and identification of associated research needs.Wellcome open research · 2020Pooled it
- Economic evaluations of onchocerciasis interventions: a systematic review and research needs.Tropical medicine & international health : TM & IH · 2019Pooled it
- Policy stakeholder perspectives on barriers and facilitators to launching a community-wide mass drug administration program for soil-transmitted helminths.Global health research and policy · 2022Trial
- Drug price trends, regional disparities, and supply shortages under China's National Volume-Based Procurement: a nationwide analysis (2018-2024).BMC health services research · 2026Article
- Cost analysis of implementing community-based mass drug administration for schistosomiasis control among adult individuals using community drug distributors in Ukerewe district council, North-Western Tanzania.PLoS neglected tropical diseases · 2026Article
- When is elimination of an infectious disease cost-effective? An analytical framework to guide elimination priorities.Cost effectiveness and resource allocation : C/E · 2026Article
- The Cost of Annual and More Frequent Than Annual Mass Drug Administration for Trachoma in Two Districts in Amhara, Ethiopia.The American journal of tropical medicine and hygiene · 2026Article
- Modelling the cost of engage & treat and test & treat strategies towards the elimination of lymphatic filariasis in Ghana.PLoS neglected tropical diseases · 2024Article
- An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- The cost of mass drug administration for trachoma in two counties of the Republic of South Sudan.PLOS global public health · 2024Article
- Cost and community acceptability of enhanced antibiotic distribution approaches for trachoma in the Republic of South Sudan: enhancing the A in SAFE (ETAS) study protocol.BMC ophthalmology · 2023Article
- Towards better antivenoms: navigating the road to new types of snakebite envenoming therapies.The journal of venomous animals and toxins including tropical diseases · 2023Article
- Using an experiment among clinical experts to determine the cost and clinical impact of rapid whole exome sequencing in acute pediatric settings.Frontiers in pediatrics · 2023Article
- Patient journey and resources mapping to implement a praziquantel mass drug administration program for children aged 5 years and below in resource-limited settings.Systematic reviews · 2022Article
- Economic evaluations of scaling up strategies of evidence-based health interventions: a systematic review protocol.BMJ open · 2021Article
- Are current preventive chemotherapy strategies for controlling and eliminating neglected tropical diseases cost-effective?BMJ global health · 2021Review
- Cost-Effectiveness Analysis in Implementation Science: a Research Agenda and Call for Wider Application.Current HIV/AIDS reports · 2021Review
- Maximising Societal Benefit From the Control of Neglected Zoonoses: Identifying Synergies and Trade-Offs in the Control ofFrontiers in veterinary science · 2021Review
- Optimizing the Number of Child Deaths Averted with Mass Azithromycin Distribution.The American journal of tropical medicine and hygiene · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
It is recognized that changing the current approaches for the control of the neglected tropical diseases will be needed to reach the World Health Organization's (WHO) 2020 goals. Consequently, it is important that economic evaluations of the alternative approaches are conducted. A vital component of such evaluations is the issue of how the intervention's costs should be incorporated. We discuss this issue-focusing on mass drug administration. We argue that the common approach of assuming an intervention's cost per treatment is constant, regardless of the number of individuals treated, is a misleading way to consider the delivery costs of mass drug administration due to the occurrence of economies/diseconomies of scale and scope. Greater care and consideration are required when the costs are incorporated into such analyses. Without this, these economic evaluations could potentially lead to incorrect policy recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.